BioNTech SE - Depositary Receipt (Common Stock) represents shares in BioNTech SE, a Germany-based biotechnology company specializing in next-generation immunotherapies. The company develops transforma... BioNTech SE - Depositary Receipt (Common Stock) represents shares in BioNTech SE, a Germany-based biotechnology company specializing in next-generation immunotherapies. The company develops transformative medicines using advanced platforms such as mRNA technology, cell therapies, bispecific antibodies, and antibody-drug conjugates. Its primary focus areas include oncology, with individualized cancer immunotherapies targeting neoantigens and tumor-specific antigens, and infectious diseases, highlighted by the Comirnaty COVID-19 vaccine developed in partnership with Pfizer. BioNTech SE operates a diverse pipeline addressing unmet medical needs in solid tumors, hematological malignancies, and vaccine-preventable diseases. This depositary receipt enables non-German investors to access BioNTech's equity, reflecting its market presence in the biotechnology sector. With institutional ownership from major funds like Baillie Gifford and Primecap Management, it underscores BioNTech's significance in innovative drug development and global health solutions, driving advancements in precision medicine and pandemic preparedness.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Biontech

We have not yet reviewed Biontech's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Biontech's data?

Start your 30-day free trial to request a data review for Biontech.

Start Free Trial

Legal Center Contact Us